Wednesday, 11 September 2013

A blast from the Past

Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, Miller D, Waldmann H, Compston A. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.Ann Neurol. 1999 Sep;46(3):296-304

The elective treatment of patients with multiple sclerosis, using a humanized anti-leukocyte (CD52) monoclonal antibody (Campath-1H), has illuminated mechanisms that underlie the clinical course of the disease. Twenty-seven patients were studied clinically and by magnetic resonance imaging (MRI) before and for 18 months after a single pulse of Campath-1H. The first dose of monoclonal antibody was associated with a transient rehearsal of previous symptoms caused by the release of mediators that impede conduction at previously demyelinated sites; this effect remained despite selective blockade of tumor necrosis factor-alpha. Disease activity persisted for several weeks after treatment but thereafter radiological markers of cerebral inflammation were suppressed for at least 18 months during which there were no new symptoms or signs. However, about half the patients experienced progressive disability and increasing brain atrophy, attributable on the basis of MRI spectroscopy to axonal degeneration, which correlated with the extent of cerebral inflammation in the pretreatment phase. These data support the formulation that inflammation and demyelination are responsible for relapses of multiple sclerosis; that inflammatory mediators, but not tumor necrosis factor-alpha, cause symptomatic reactivation of previously demyelinated lesions; and that axonal degeneration, conditioned by prior inflammation but proceeding despite its suppression, contributes to the progressive phase of disability. These results provide evidence supporting the emerging view that treatment in multiple sclerosis must be given early in the course, before the consequences of inflammation are irretrievably established.

This was such an informative paper and shows that treatment failures can be as informative as treatment successes.

3 comments:

  1. It is imperative that this message of early treatment is conveyed to and learnt by, GPs and neurologists working at a local level, otherwise more people will be denied access to treatment through well meaning ignorance. How can this happen?

    ReplyDelete
    Replies
    1. By hammering home the message on this blog (which appears to be widely read by those with influence), in conferences and journal articles. If you keep banging your head against a brick wall, eventually some bricks are loosened!

      Delete
  2. Yes, I am aware that this blog has come to the fond attention of some influential Antipodeans.

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.